Printer Friendly

Sirtex Medical collaborates with MIM Software.

M2 PHARMA-February 13, 2020-Sirtex Medical collaborates with MIM Software

(C)2020 M2 COMMUNICATIONS

Sirtex Medical, a manufacturer of targeted liver cancer therapies, announced on Wednesday, that it has collaborated with MIM Software Inc, a global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging.

According to the terms of the contract, Sirtex's specialised sales teams in the United States, Europe and other key global markets are to offer MIM SurePlanTM LiverY90 software alongside the company's SIR-Spheres Y-90 resin microspheres to improve treatment precision for patients with hepatic tumours.

MIM SurePlan LiverY90 offers tools and post-treatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumours with SIR-Spheres. The software is claimed to enable physicians to calculate the dose delivered by the microspheres to improve treatment decisions and patient care. The technology also includes CT, PET, SPECT and MRI scans simultaneously to deliver results on spheres deposition, coverage and absorbed dose, enabling physicians to make informed decisions faster about next steps.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 13, 2020
Words:181
Previous Article:Synspira Therapeutics signs contract with Cystic Fibrosis Foundation.
Next Article:Prescient adds new members to Advisory business.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters